Tema Etfs LLC Boosts Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Tema Etfs LLC increased its investment in Thermo Fisher Scientific by 165.2%, acquiring 4,185 additional shares, making it the 26th largest holding in their portfolio.
• Thermo Fisher Scientific reported $5.36 earnings per share, surpassing expectations, with revenue of $10.86 billion for the most recent quarter.
• The company announced a quarterly dividend of $0.43 per share, with a payout ratio of 9.95%, signaling a commitment to returning value to shareholders.

Tema Etfs LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 165.2% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,719 shares of the medical research company's stock after purchasing an additional 4,185 shares during the period. Thermo Fisher Scientific comprises about 1.0% of Tema Etfs LLC's investment portfolio, making the stock its 26th biggest position. Tema Etfs LLC's holdings in Thermo Fisher Scientific were worth $3,343,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. GAMMA Investing LLC increased its holdings in shares of Thermo Fisher Scientific by 60,610.9% in the first quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares during the last quarter. Nuveen LLC bought a new stake in Thermo Fisher Scientific during the first quarter worth approximately $532,360,000. Farallon Capital Management LLC grew its stake in shares of Thermo Fisher Scientific by 73.8% during the fourth quarter. Farallon Capital Management LLC now owns 1,233,256 shares of the medical research company's stock valued at $641,577,000 after buying an additional 523,800 shares during the last quarter. Sarasin & Partners LLP bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at approximately $242,991,000. Finally, Two Sigma Advisers LP grew its stake in shares of Thermo Fisher Scientific by 81.6% during the fourth quarter. Two Sigma Advisers LP now owns 933,200 shares of the medical research company's stock valued at $485,479,000 after buying an additional 419,200 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Up 0.7%

NYSE TMO traded up $3.31 during trading on Friday, hitting $493.05. The company's stock had a trading volume of 1,228,194 shares, compared to its average volume of 1,910,751. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The company has a market cap of $186.18 billion, a PE ratio of 28.52, a P/E/G ratio of 2.63 and a beta of 0.74. The business's 50 day simple moving average is $452.50 and its 200-day simple moving average is $454.32. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the prior year, the firm earned $5.37 EPS. The firm's revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,697,567.04. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,896 shares of company stock worth $13,603,438 in the last 90 days. Company insiders own 0.33% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Evercore ISI dropped their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. William Blair started coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an "outperform" rating on the stock. Robert W. Baird increased their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Finally, Barclays increased their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.